Agomab Therapeutics NV Adrs (AGMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | |
| Cash Flows From Operating Activities | ||
| Net Income | -70,766 | -50,066 |
| Depreciation Amortization | 248 | 337 |
| Accounts payable and accrued liabilities | 2,669 | -249 |
| Other Working Capital | 459 | -1,387 |
| Other Operating Activity | 8,850 | 693 |
| Operating Cash Flow | $-58,540 | $-50,673 |
| Cash Flows From Investing Activities | ||
| Change In Deposits | -33,942 | N/A |
| PPE Investments | -5 | -730 |
| Other Investing Activity | -3,394 | 0 |
| Investing Cash Flow | $-37,341 | $-730 |
| Cash Flows From Financing Activities | ||
| Common Stock Issued | N/A | 105,023 |
| Other Financing Activity | -382 | -317 |
| Financing Cash Flow | $-382 | $104,706 |
| Exchange Rate Effect | 51 | -221 |
| Beginning Cash Position | 193,989 | 132,451 |
| End Cash Position | 97,773 | 185,536 |
| Net Cash Flow | $-96,215 | $53,085 |
| Free Cash Flow | ||
| Operating Cash Flow | -58,540 | -50,673 |
| Capital Expenditure | -5 | -730 |
| Free Cash Flow | -58,544 | -51,403 |